28-Mar-2024
Fortress Biotech GAAP EPS of -$8.47 beats by $0.64, revenue of $84.51M beats by $4.83M
Seeking Alpha News (Thu, 28-Mar 4:57 PM ET)
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 28-Mar 4:05 PM ET)
Mustang Bio stock climbs 9% amid drug development update
Seeking Alpha News (Thu, 28-Mar 11:09 AM ET)
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Globe Newswire (Thu, 28-Mar 9:00 AM ET)
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Globe Newswire (Mon, 25-Mar 8:30 AM ET)
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Globe Newswire (Fri, 22-Mar 8:30 AM ET)
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 21-Mar 4:01 PM ET)
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Globe Newswire (Mon, 18-Mar 4:05 PM ET)
Globe Newswire (Mon, 18-Mar 8:30 AM ET)
Globe Newswire (Mon, 18-Mar 8:00 AM ET)
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Fortress Biotech trades on the NASDAQ stock market under the symbol FBIO.
As of March 28, 2024, FBIO stock price declined to $2.00 with 309,039 million shares trading.
FBIO has a beta of 3.69, meaning it tends to be more sensitive to market movements. FBIO has a correlation of 0.10 to the broad based SPY ETF.
FBIO has a market cap of $36.75 million. This is considered a Sub-Micro Cap stock.
Last quarter Fortress Biotech reported $35 million in Revenue and -$.94 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $2.27.
In the last 3 years, FBIO stock traded as high as $91.50 and as low as $1.24.
The top ETF exchange traded funds that FBIO belongs to (by Net Assets): VTI, VXF, FESM.
FBIO has underperformed the market in the last year with a return of -82.2%, while the SPY ETF gained +33.6%. In the last 3 month period, FBIO fell short of the market, returning -42.9%, while SPY returned +10.1%. However, in the most recent 2 weeks FBIO has outperformed the stock market by returning +9.9%, while SPY returned +1.7%.
FBIO support price is $2.02 and resistance is $2.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBIO stock will trade within this expected range on the day.